Federico Simone

Intellectual Property Attorney

T 312-876-1400   |  F 978-268-8715

federico.simone@evanlawgroup.com

V-card

PRACTICE

Federico Simone's practice focuses on biotechnology and pharmacology patent prosecution and other intellectual property matters.

Mr. Simone received his J.D. from Loyola University Chicago School of Law. While in law school, Mr. Simone was a Law Clerk and Technology Specialist at Evan Law Group. Prior to entering law school, Mr. Simone was a research scientist at the University of Chicago for 12 years, working in the laboratory of Professor Michael J. Thirman. His work focused on identifying and characterizing genes involved in chromosomal translocation, using a broad range of biotechnological techniques, including a yeast two-hybrid system; bacterial and yeast cell transformation, human cell transfection, fluorescent cell sorting, ELISA, gene reporters, and Western, Southern, and Northern blots, as well as other related techniques.

Prior to attending the University of Chicago, Mr. Simone was a research fellow at the Referral Centre for Oncology (Centro di Riferimento Oncologico) in Aviano, Italy. He attended the University of Trieste in Italy and is fluent in Italian.

Mr. Simone has authored numerous scientific papers on leukemia, molecular biology, ovarian cancer genetics, and multidrug-resistance pharmacology.

BAR ADMISSIONS

• Admitted to practice law in Illinois
• Registered Patent Agent, U.S. Patent and Trademark Office

EDUCATION

• Loyola University Chicago School of Law, J.D., 2011
• University of Trieste, Trieste, Italy, M.S. Biology, with honors, 1992

SELECTED PUBLISHED ARTICLES

• Hahn J., Xiao W., Jiang F., Simone F., Thirman, M.J., Wang Z. Apoptosis induction and growth suppression by U19 is mediated through its ELL-binding domain. Prostate, 67(2):146-53, 2007.
• Pascal-Le Tallec L., Simone F., Viengchareun S., Meduri G., Thirman M.J., Lombes M. The elongation factor ELL (eleven-nineteen lysine-rich leukemia) is a selective coregulator for steroid receptor functions. Mol Endocrinol, 19(5):1158-69, 2005.
• Polak P.E., Simone F., Kaberlein J.J., Luo R.T., Thirman M.J. ELL and EAF1 are Cajal body components that are disrupted in MLL-ELL leukemia. Mol Biol Cell, 14(4):1517-28, 2003.
• Simone F., Luo R.T., Polak P.E., Kaberlein J.J., Thirman M.J. ELL-associated factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties. Blood, 101(6):2355-62, 2003.
• Baron B.W., Anastasi J., Thirman M.J., Furukawa Y., Fears S., Kim D.C., Simone F., Birkenbach M., Montag A., Sadhu A., Zeleznik-Le N., McKeithan T.W. The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: implications for a role of BCL6 in the down-regulation of apoptosis. Proc Natl Acad Sci U S A, 99(5):2860-5, 2002.
• Luo R.T., Simone F., Polak P.E., Kawamata S., Thirman M.J. The elongation domain of ELL is dispensable but its EAF1 interaction domain is essential for MLL-ELL induced leukemogenesis. Mol Cell Biol, (16):5678-87, 2001.
• Simone F., Polak P.E., Kaberlein J.J., Luo R.T., Levitan D.A., Thirman M.J. EAF1, a novel ELL-associated factor that is delocalized by expression of the MLL-ELL fusion protein. Blood, 98(1):201-9, 2001.
• Viel A., Dall'Agnese L., Simone F., Canzonieri V., Capozzi E., Visentin M.C., Valle R., Boiocchi M. Loss of heterozygosity at the 5, 10-methylenetetrahydrofolate reductase locus in human ovarian carcinomas. British Journal of Cancer, 75:1105-10, 1997.
• Toffoli G., Corona G., Simone F., Gigante M., De Angeli S., Boiocchi M. Cellular pharmacology of idarubicinol (IDO) in multidrug resistance LoVo cell lines. International Journal of Cancer, 67:129-37, 1996.
• Toffoli G., Simone F., Corona G., Raschack M., Cappelletto B., Gigante M. and Boiocchi M. Structure-activity relationship in verapamil analogs and reversal of MDR resistance. Biochem Pharmacol, 50:1245-55, 1995.
• Toffoli G., Simone F., Gigante M. and Boiocchi M. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines. Biochem Pharmacol, 48:1871-81, 1994.

PROFESSIONAL MEMBERSHIPS

• American Bar Association
• American Intellectual Property Law Association
• Illinois State Bar Association

LANGUAGES SPOKEN

• Fluent in Italian